Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018;5(4):245-252.
doi: 10.14283/jpad.2018.35.

Clinical Application of APOE in Alzheimer's Prevention: A Precision Medicine Approach

C L Berkowitz  1 , L Mosconi, A Rahman, O Scheyer, H Hristov, R S Isaacson
Affiliations
Review

Clinical Application of APOE in Alzheimer's Prevention: A Precision Medicine Approach

C L Berkowitz et al. J Prev Alzheimers Dis. 2018.

Abstract

Population-attributable risk models estimate that up to one-third of Alzheimer's disease (AD) cases may be preventable through risk factor modification. The field of AD prevention has largely focused on addressing these factors through universal risk reduction strategies for the general population. However, targeting these strategies in a clinical precision medicine fashion, including the use of genetic risk factors, allows for potentially greater impact on AD risk reduction. Apolipoprotein E (APOE), and specifically the APOE ε4 variant, is one of the most well-established genetic influencers on late-onset AD risk. In this review, we evaluate the impact of APOE ε4 carrier status on AD prevention interventions, including lifestyle, nutrigenomic, pharmacogenomic, AD comorbidities, and other biological and behavioral considerations. Using a clinical precision medicine strategy that incorporates APOE ε4 carrier status may provide a highly targeted and distinct approach to AD prevention with greater potential for success.

Keywords: APOE; Alzheimer’s disease; Alzheimer’s disease prevention; apolipoprotein ε4; clinical precision medicine.

PubMed Disclaimer

Conflict of interest statement

Dr. Isaacson has served as a scientific advisor for Neurotrack and 23 and Me.All other authors declare no conflict of interest.The funders had no role in the study design, data collection or analysis, decision to publish, or preparation of the manuscript.

References

    1. Epidemiology of Alzheimer disease. 2012;2(8) - PMC - PubMed
    1. Sperling R.A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging–Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280–292. 10.1016/j.jalz.2011.03.003 PubMed PMID: 21514248, PMCID 3220946. - DOI - PMC - PubMed
    1. Livingston G., et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673–2734. 10.1016/S0140-6736(17)31363-6 PubMed PMID: 28735855. - DOI - PubMed
    1. Burke J.R., Roses A.D. Genetics of Alzheimer's disease. Int J Neurol. 1991;25–26:41–51. PubMed PMID: 11980062. - PubMed
    1. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622–630. 10.1126/science.3283935 PubMed PMID: 3283935. - DOI - PubMed

Publication types